Table 1.

Currently FDA‐approved antivirals against influenza.

Class of antiviral	Name	Commercial name	Year of approval	Administration route	Treatment regime	Mutations associated with resistance	% Of resistant strains circulating	References
M2 inhibitors	Amantadine	Symmetrel a	1966	Oral	200 mg·day−1 in 1 or 2 divided doses	M2 (L26F, V27A, A30V, S31N, G34E, and L38F)	99.9% (H1N1 and H3N2 strains) 45.2% (H1‐H17) 13% H5N1	[6, 7, 8, 14, 16, 17]
	Rimantadine	Flumadine	1993	Oral	100 mg twice a day for 7 days
NA inhibitors	Oseltamivir	Tamiflu	2016	Oral	75 mg twice a day for 5 days	NA (H274Y, I222R/K/V, G146R, E119A/G/D, Q136K, R292K, N295S, V116A, and H117V)	1.3 ‐ 3.2% (H1N1) and < 1% (H3N2 and IBV)	[21, 25, 26, 27, 38, 39]
	Peramivir	Rapivab	2014	Intravenous	600mg, single dose within 2 days after onset of symptoms
	Zanamivir	Relenza	1999	Inhalation	10 mg twice a day for 5 days
PA inhibitor	Baloxavir	Xofluza	2018	Oral	40mg (weight < 80 kg) or 80 mg (weight > 80 kg) one dose	PA (I38T, I38F, and I38M, E23G/K, A37T, and E199G)	9.7% after baloxavir treatment	[4, 48, 49, 50, 52, 53, 58]

^a Discontinued.